{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:28:35Z","timestamp":1787027315791,"version":"build-2736575974"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Transplant."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICI) are standard of care therapy for patients with cutaneous malignancies, the most frequently diagnosed cancers in solid organ transplant (SOT) recipients. The activity and rate of allograft rejection in SOT recipients with advanced skin cancers treated with ICI is understudied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of SOT recipients with advanced melanoma, cutaneous squamous cell carcinoma (cSCC), and merkel cell carcinoma (MCC) who were treated with ICI. Unpublished cases from our institution and published cases from the literature were aggregated. Demographics, type of immunosuppressive therapy, type of ICI(s) administered, prior systemic therapies, tumor response to ICI, and evidence of organ rejection and\/or failure were recorded. Objective response rates (ORR) and rates of graft rejection and failure are reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety patients were identified; four patients from our institution and 86 unique patients from a literature review. ORR to first-line ICI for the entire cohort was 41.1% (37\/90). ORR by tumor type was 31% (18\/58), 64.3% (18\/28), and 25.0% (1\/4) for melanoma, cSCC, and MCC, respectively. The rate of graft rejection was 37.8% (34\/90) with 61.8% (21\/34) of these cases progressing to graft failure. Number of immunosuppressive agents (0, 1, 2, or 3) was inversely associated with rate of graft failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective analysis, ICIs demonstrate clinical activity in SOT recipients with cutaneous malignancies; however, the rate of graft rejection is high. Treatment plans should be individualized through thorough interdisciplinary discussion. Immunosuppressive modifications may be considered prior to starting treatment, but when feasible, enrollment on clinical trials is preferred.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frtra.2023.1284740","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T07:05:47Z","timestamp":1698649547000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies"],"prefix":"10.3389","volume":"2","author":[{"given":"Stephanie","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pachella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Groisberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"B1","unstructured":""},{"key":"B2","volume-title":"US counts millionth organ transplant while pushing for more","author":"Neergaard","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00002018-200023020-00002","article-title":"Post-transplant malignancy: the role of immunosuppression","volume":"23","author":"Penn","year":"2000","journal-title":"Drug Saf"},{"key":"B4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.1097\/01.tp.0000186382.81130.ba","article-title":"Malignancy after transplantation","volume":"80","author":"Buell","year":"2005","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jaad.2010.11.062","article-title":"Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients","volume":"65","author":"O\u2019Reilly Zwald","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.det.2011.02.004","article-title":"Management of skin cancer in solid-organ transplant recipients: a multidisciplinary approach","volume":"29","author":"Greenberg","year":"2011","journal-title":"Dermatol Clin"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jamadermatol.2016.4920","article-title":"Incidence of and risk factors for skin cancer in organ transplant recipients in the United States","volume":"153","author":"Garrett","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1056\/NEJMe1006416","article-title":"Treating cancer by targeting the immune system","volume":"363","author":"Hwu","year":"2010","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1600-6143.2005.00823.x","article-title":"CTLA4 engagement is required for induction of murine liver transplant spontaneous tolerance","volume":"5","author":"Li","year":"2005","journal-title":"Am J Transplant"},{"key":"B14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/TP.0000000000000169","article-title":"Co-inhibitory pathways and their importance in immune regulation","volume":"98","author":"Murakami","year":"2014","journal-title":"Transplantation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/j.1600-6143.2011.03451.x","article-title":"Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts","volume":"11","author":"Riella","year":"2011","journal-title":"Am J Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/CIRCULATIONAHA.107.741025","article-title":"Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy","volume":"117","author":"Yang","year":"2008","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1080\/0284186X.2018.1479069","article-title":"Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients","volume":"57","author":"Smedman","year":"2018","journal-title":"Acta Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-015-0066-0","article-title":"Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation","volume":"3","author":"Morales","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/mmt.15.27","article-title":"Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus","volume":"2","author":"Qin","year":"2015","journal-title":"Melanoma Manag"},{"key":"B25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/CJI.0000000000000077","article-title":"Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma","volume":"38","author":"Ranganath","year":"2015","journal-title":"J Immunother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/ajt.13711","article-title":"Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection","volume":"16","author":"Alhamad","year":"2016","journal-title":"Am J Transplant"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/annonc\/mdw293","article-title":"Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient","volume":"27","author":"Gastman","year":"2016","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejca.2016.07.026","article-title":"Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient","volume":"67","author":"Herz","year":"2016","journal-title":"Eur J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1016\/j.transproceed.2016.07.019","article-title":"Renal allograft failure after ipilimumab therapy for metastatic melanoma: a case report and review of the literature","volume":"48","author":"Jose","year":"2016","journal-title":"Transplant Proc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40425-016-0171-8","article-title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","volume":"4","author":"Ong","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma","volume":"27","author":"Spain","year":"2016","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1097\/TP.0000000000001861","article-title":"Severe allograft rejection and autoimmune hemolytic Anemia after anti-PD1 therapy in a kidney transplanted patient","volume":"101","author":"Deltombe","year":"2017","journal-title":"Transplantation"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/annonc\/mdx281","article-title":"Acute liver graft rejection after ipilimumab therapy","volume":"28","author":"Dueland","year":"2017","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/CJI.0000000000000180","article-title":"Immune checkpoint inhibitors in organ transplant patients","volume":"40","author":"Kittai","year":"2017","journal-title":"J Immunother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13256-017-1229-z","article-title":"Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report","volume":"11","author":"Kwatra","year":"2017","journal-title":"J Med Case Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s40425-018-0437-4","article-title":"Kaposi\u2019s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab","volume":"6","author":"Miller","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00262-016-1918-2","article-title":"Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report","volume":"66","author":"Owonikoko","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.7326\/L17-0187","article-title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma","volume":"167","author":"Schvartsman","year":"2017","journal-title":"Ann Intern Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CJI.0000000000000188","article-title":"Safe administration of an anti-PD-1 antibody to kidney-transplant patients: 2 clinical cases and review of the literature","volume":"40","author":"Winkler","year":"2017","journal-title":"J Immunother"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the mayo clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"MMT10","DOI":"10.2217\/mmt-2018-0004","article-title":"Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations","volume":"5","author":"Grant","year":"2018","journal-title":"Melanoma Manag"},{"key":"B43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/CMR.0000000000000410","article-title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review","volume":"28","author":"Kuo","year":"2018","journal-title":"Melanoma Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejca.2018.03.019","article-title":"Checkpoint blockade after kidney transplantation","volume":"96","author":"Lesouhaitier","year":"2018","journal-title":"Eur J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1200\/JOP.2017.027326","article-title":"Complete tumor response to pembrolizumab and allograft preservation in renal allograft recipient on immunosuppressive therapy","volume":"14","author":"Sadaat","year":"2018","journal-title":"J Oncol Pract"},{"key":"B46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1111\/ajt.15071","article-title":"Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients","volume":"18","author":"Zehou","year":"2018","journal-title":"Am J Transplant"},{"key":"B48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s40425-019-0653-6","article-title":"Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/lt.25622","article-title":"Checkpoint inhibitor-induced rejection of a liver allograft: a combination of acute T cell-mediated and antibody-mediated rejection","volume":"25","author":"Lee","year":"2019","journal-title":"Liver Transpl"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/TP.0000000000002502","article-title":"Preserved renal allograft function and successful treatment of metastatic merkel cell cancer post nivolumab therapy","volume":"103","author":"Singh","year":"2019","journal-title":"Transplantation"},{"key":"B53","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/0284186X.2020.1747637","article-title":"Pembrolizumab as first line treatment of merkel cell carcinoma patients\u2013a case series of patients with various co-morbidities","volume":"59","author":"Bystrup Boyles","year":"2020","journal-title":"Acta Oncol (Madr)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00262-020-02644-2","article-title":"Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy","volume":"69","author":"Danesh","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B55","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CMR.0000000000000651","article-title":"The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma","volume":"30","author":"Hanna","year":"2020","journal-title":"Melanoma Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1002\/cncr.33134","article-title":"Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: a single-center analysis","volume":"126","author":"Owoyemi","year":"2020","journal-title":"Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.transproceed.2019.09.014","article-title":"Use of ipilimumab and pembrolizumab in metastatic melanoma in a combined heart and kidney transplant recipient: a case report","volume":"52","author":"Soellradl","year":"2020","journal-title":"Transplant Proc"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e000908","DOI":"10.1136\/jitc-2020-000908","article-title":"Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients","volume":"8","author":"Trager","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/TP.0000000000002914","article-title":"Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients","volume":"104","author":"Venkatachalam","year":"2020","journal-title":"Transplantation"},{"key":"B61","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jdcr.2021.05.012","article-title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with autoimmune disease and metastatic cutaneous squamous cell carcinoma","volume":"14","author":"Brumfiel","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/ced.15018","article-title":"Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus","volume":"47","author":"Gambichler","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"660795","DOI":"10.3389\/fimmu.2021.660795","article-title":"Case report: single dose anti-PD1 in a patient with metastatic melanoma and cardiac allograft","volume":"12","author":"Goodman","year":"2021","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e656","DOI":"10.1097\/TXD.0000000000001113","article-title":"Utility of serial donor-derived cell-free DNA measurements for detecting allograft rejection in a kidney transplant recipient after PD-1 checkpoint inhibitor administration","volume":"7","author":"Lakhani","year":"2021","journal-title":"Transplant Direct"},{"key":"B65","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/curroncol28010057","article-title":"Safe administration of cemiplimab to a kidney transplant patient with locally advanced squamous cell carcinoma of the scalp","volume":"28","author":"Paoluzzi","year":"2021","journal-title":"Curr Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e238037","DOI":"10.1136\/bcr-2020-238037","article-title":"Acute renal transplant rejection following nivolumab therapy for metastatic melanoma","volume":"14","author":"Tan","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B67","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/onco.13539","article-title":"A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma","volume":"26","author":"Tsung","year":"2021","journal-title":"Oncologist"},{"key":"B68","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.annder.2022.01.003","article-title":"Efficacy of nivolumab in the treatment of metastatic cutaneous squamous cell carcinoma in a kidney-transplant patient with a history of allograft rejection","volume":"149","author":"Bastos","year":"2022","journal-title":"Ann Dermatol Venereol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/jdv.17407","article-title":"Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy","volume":"36","author":"O'Connell","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","article-title":"Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review","volume":"20","author":"Portuguese","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.3748\/wjg.v25.i25.3123","article-title":"Revisiting the liver\u2019s role in transplant alloimmunity","volume":"25","author":"Abrol","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review","volume":"82","author":"Fisher","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"B76","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1634\/theoncologist.2018-0195","article-title":"Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue","volume":"24","author":"Aguirre","year":"2019","journal-title":"Oncologist"},{"key":"B79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2217\/imt-2021-0195","article-title":"Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review","volume":"14","author":"Rossi","year":"2022","journal-title":"Immunotherapy"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1097\/tp.0000000000004459","article-title":"Immune checkpoint inhibitors in solid organ transplant recipients with advanced skin cancers-emerging strategies for clinical management","volume":"107","author":"Ferr\u00e1ndiz-Pulido","year":"2023","journal-title":"Transplantation"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.4240\/wjgs.v13.i10.1267","article-title":"Immunotherapy after liver transplantation: where are we now?","volume":"13","author":"Au","year":"2021","journal-title":"World J Gastrointest Surg"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","volume":"20","author":"d\u2019Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"key":"B84","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/MOT.0000000000001036","article-title":"Immune checkpoint inhibitors in kidney transplantation","volume":"28","author":"Alzahrani","year":"2023","journal-title":"Curr Opin Organ Transplant"},{"key":"B85","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1200\/JCO.2022.40.16_suppl.9507","article-title":"Nivolumab (NIVO)\u2009+\u2009tacrolimus (TACRO)\u2009+\u2009prednisone (PRED) +\/\u2212 ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers","volume":"40","author":"Schenk","year":"2022","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"9519","DOI":"10.1200\/JCO.2023.41.16_suppl.9519","article-title":"Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1","volume":"41","author":"Hanna","year":"2023","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41467-023-37230-4","article-title":"Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy","volume":"14","author":"Dunlap","year":"2023","journal-title":"Nat Commun"}],"container-title":["Frontiers in Transplantation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2023.1284740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T07:05:56Z","timestamp":1698649556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2023.1284740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":88,"alternative-id":["10.3389\/frtra.2023.1284740"],"URL":"https:\/\/doi.org\/10.3389\/frtra.2023.1284740","relation":{},"ISSN":["2813-2440"],"issn-type":[{"value":"2813-2440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"article-number":"1284740"}}